/PRNewswire/ SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases.
/PRNewswire/ The "Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com s offering..
/PRNewswire/ The "Asia-Pacific Nucleic Acid Therapeutics CDMO Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com s.
The Global Antisense Oligonucleotides Market Revenue is predicted to earn US$ 5,659.2 million in revenue by 2032, up from US$ 1,921.6 million in 2022, at a CAGR of 10.3% during the forecast period.Antisense Oligonucleotides (ASOs) are a promising class of therapeutic agents that hold tremendous potential in the fiel.
According to the report, the global RNA based therapeutics industry was estimated at $4.93 billion in 2021, and is anticipated to hit $25.12 billion by 2030, registering a CAGR of 17.6% from 2021 to 2030. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investme.